XBP1 and acute lymphoblastic leukemia: Nevertheless, the ratio between spliced and unspliced forms of XBP1 is associated with sensitivity to bortezomib only in the BCP-ALL cohort of patients, suggesting that spliced XBP1 may be indicative of bortezomib response in BCP-ALL.